Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010

Patricia I. Jewett, Ronald E. Gangnon, Amy Trentham-Dietz, Brian L. Sprague

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

OBJECTIVE: To estimate long term trends in estrogen-progestin prevalence for the U.S. female population by year and age.

METHODS: We integrated data on oral estrogen-progestin use from the National Health and Nutrition Examination Survey 1999-2010 with data from the National Prescription Audit 1970-2003. Distributions of estrogen-progestin by age from the National Health and Nutrition Examination Survey were applied to the prescription data, and calibration and interpolation procedures were used to generate estrogen-progestin prevalence estimates by single year of age and single calendar year for 1970-2010.

RESULTS: Estimated prevalence of oral estrogen-progestin was below 0.5% in the 1970s, began to rise in the early 1980s, and almost tripled between 1990 and the late 1990s. The age-adjusted prevalence for women aged 45-64 years peaked at 13.5% in 1999 with highest use among 57-year-old women (23.2%). Prevalence of estrogen-progestin use declined dramatically in the early 2000s with only 2.7% of women aged 45-64 years using estrogen-progestin in 2010, which is comparable to prevalence levels in the mid-1980s.

CONCLUSION: The dramatic rise and fall of estrogen-progestin use over the past 40 years provides an illuminating case study of prescription practices before, during, and after the development of evidence regarding benefits and harms.

Original languageEnglish (US)
Pages (from-to)727-733
Number of pages7
JournalObstetrics and gynecology
Volume124
Issue number4
DOIs
StatePublished - Oct 10 2014

Fingerprint Dive into the research topics of 'Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010'. Together they form a unique fingerprint.

Cite this